Regulatory Insights

  1. How Remote Pharmacy Monitoring Improves Trial Compliance 6/10/2026

    Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

  2. Successful SwissMedic Marketing Authorization Application For An Oncology Therapy 6/4/2026

    See how strategic EU dossier adaptation and Swiss-specific regulatory expertise enabled a successful SwissMedic submission and accelerated market access for an oncology therapy.

  3. FDA Expedited Programs – What You Need To Know 6/4/2026

    Explore FDA expedited programs and learn how Fast Track, Breakthrough Therapy, RMAT, Priority Review, and more can help accelerate development and bring therapies to patients sooner.

  4. End-To-End Clinical, Biometrics, And Regulatory Support In Neurology 6/4/2026

    Discover how an integrated NDA strategy aligned data, vendors, and regulatory execution to achieve an on-time submission and approval without major FDA queries.

  5. Ethical & Regulatory Considerations For Pediatric Gene Therapy 5/28/2026

    Understanding risk thresholds, consent requirements, and IRB expectations early can prevent redesign, reduce delays, and improve trial feasibility for vulnerable patient populations

  6. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  7. Where PRO Strategy Goes Wrong 5/27/2026

    PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

  8. Is The Industry Ready To Trust LLMs With Chart Review? 5/27/2026

    See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

  9. AI, Virtual Participants, and the Evolving FDA Regulatory Landscape 5/27/2026

    Understanding emerging requirements around transparency, risk, and governance is essential for responsibly advancing AI-driven innovation in regulated environments.

  10. Simultaneous Submissions And Managing Multiple Regulatory Pathways 5/27/2026

    Global regulators are increasingly aligned, creating new opportunities for sponsors to pursue near-simultaneous submissions across major markets